Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding

Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced the closing of a $25.6m Series B financing round led by Horizons Ventures with additional investment from Luminous Ventures, SOSV and select other individual and large family office investors. Synthace will use the new funds to drive continued product development and build upon its cell and gene therapy customer base to accelerate global awareness of its solutions.

Read More
NewsThe Synthace Teambiology
ATMPs: Opportunities and Challenges | PDA’s ATMP Conference 2018

Earlier this month, I attended the PDA’s 10th annual Conference on Advanced Therapy Medicinal Products (ATMPs) in Amsterdam. Over the past ten years, the conference has provided a forum to discuss opportunities and challenges in the space. The topics covered were wide-ranging – from R&D and manufacturing best practice right through to the clinical application of ATMPs.

Read More
Synthace Named a 2018 Cool Vendor in Life Sciences by Gartner

Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced it has been recognised in Gartner Inc.'s "Cool Vendors in Life Sciences" report published on June 6, 2018. The companies named in this report represent a look into the new and innovative vendors, products and services in the global Life Sciences market.

Read More